Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

SIMPLE SUMMARY: Targeted therapy and chemotherapy are the mainstays of treatment to improve the survival of patients with metastatic colorectal cancer (mCRC). When RAS and BRAF genes are normal, a molecular target treatment with an anti-EGFR antagonist is prescribed. Anti-EGFR antagonists induce ski...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Ting-Yu, Hsu, Hung-Chih, Chern, Yih-Jong, Liao, Chun-Kai, Hsu, Yu-Jen, Tsai, Wen-Sy, Hsieh, Pao-Shiu, Lin, Yu-Fen, Lee, Hsiu-Lan, You, Jeng-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046585/
https://www.ncbi.nlm.nih.gov/pubmed/36980549
http://dx.doi.org/10.3390/cancers15061663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046585/
https://www.ncbi.nlm.nih.gov/pubmed/36980549
http://dx.doi.org/10.3390/cancers15061663

Ejemplares similares